

Guidelines for clinical case submission

Opening of clinical case submission:

February 23, 2026; 10:00 CET

Deadline for clinical case submission:

April 24, 2026; 23:59 CEST

Notification of acceptance/rejection:

by mid-July 2026

Deadline for confirmation/withdrawal/changes:

July 22, 2026

How to submit a clinical case:

1. Clinical cases may only be submitted online via the conference website, [Week | UEG - United European Gastroenterology](#). Abstracts sent by post, e-mail or fax will not be accepted (deadline of April 24, 2026).
2. Authors must follow clinical case submission guidelines; non-compliant clinical cases will not be sent for review.
3. Clinical cases may be saved as drafts, but they must be submitted before the deadline; **only submitted clinical cases will be reviewed**.
4. The submission system will generate a temporary clinical case number upon submission that must be used in all correspondence. If you do not receive this number immediately after your submission, your clinical case has not been registered. Please also check your spam folder if you have not received this number.
5. The e-mail address provided for clinical case submission must be fully functional and configured to allow all notifications from the UEG Headquarters Management and abstract management team.

General guidelines:

1. Clinical cases must be submitted and presented in English.
2. Please ensure that your clinical case does not contain spelling, grammatical or scientific errors, as it will be reproduced exactly as submitted.
3. Clinical cases will be reviewed by a panel of experts and may be selected for poster presentation (or may be rejected).
4. By submitting a clinical case, the author agrees to present it at the session and time assigned by the UEG Scientific Committee. If an author cannot present, they should inform the organisers with a valid reason.
5. **Clinical Case Eligibility and Prior Publication:**
 - Clinical cases will not be considered for presentation if they have been published as a full article or paper or if they have been accepted for publication (including manuscripts) in printed or electronic formats upon the submission deadline.
 - Clinical cases presented previously at national or international meetings may be submitted providing this is declared, but we particularly welcome work not previously presented at international meetings.

Content of an abstract:

1. The clinical case title should clearly indicate the nature of the investigation.
2. Abbreviations must not be used in titles, though they are acceptable in the text, provided they are explained upon first use.
3. Choose one primary topic from the submission system that most accurately reflects your clinical case.
4. The clinical case abstract should be as informative as possible:
 - Stick to one specific case instead of a case series.
 - Describe the clinical history of the patient and relevant biological data.
 - Summarise the investigations performed and differential diagnoses.
 - At this stage, clarify the difficult and original aspects of the case.
 - Provide the final diagnosis.
 - Summarise the therapeutic approach.
 - State the points to be discussed (avoid literature review or guidelines compliance).
5. A clinical case summary (**maximum 2,000 characters including spaces**) must be provided, together with references (maximum 200 words) to illustrative material such as endoscopic, radiological, and pathological images, as well as innovative physiological or other research data. The actual illustrative material should not be submitted, as image upload is not possible; however, a list of the images intended for inclusion on the poster, should the case be accepted, must be supplied.
6. The use of trademarks is prohibited; only International Non-proprietary Names (INN), e.g. generic drug names, are allowed.
7. Indicate a minimum of 2 to 3 keywords that reflect your clinical case content.
8. There is an **author limit of 50 authors**; study groups can be included in a separate section.
9. Statements such as 'data will be presented' instead of providing the actual data within the abstract will lead to automatic rejection.

Usage of Artificial Intelligence (AI):

1. Using publicly available generative AI as a basic tool to support authors in refining, correcting, formatting and editing texts is permissible. Authors must always consider copyright, privacy and confidentiality implications before uploading text and other information to generative AI platforms for permitted purposes.
2. Generative AI must not be used to create, alter, or manipulate original research data and results.

Conflict of interest:

1. As UEG intends to provide high-quality sessions focused on educational content that is free from commercial influence or bias, all potential conflicts of interest need to be declared.
2. The submitting author of a clinical case is **requested to declare any potential conflict of interest for all authors** during the abstract submission. Moreover, the authors'

names (full first names, family names), gender and affiliation (places of work/institution, city, country) must be provided.

Registration and travel grants:

1. The **presenting author must register** for the congress **by September 23, 2026**, or withdraw the clinical case. Accepted clinical case presenters benefit from the extended early bird registration fee and will receive a separate email from the official housing and registration partner.
2. The registration fee for the presenting author will not be waived.

Acceptance and rejection notification:

1. Notification of acceptance or rejection will be mailed to the submitter and the presenting author at the **e-mail address supplied on the submission form by mid-July 2026** at the latest.
2. Further presentation instructions will be issued nearer to the congress, and poster upload is mandatory for all accepted posters prior to the UEG Week.

Presenter changes and withdrawals:

1. If the original presenting author is unable to present the clinical case, it is that person's responsibility to ensure that one of the co-authors takes over this role.
2. If you need to **change the presenting author or withdraw your clinical case**, you can do so via the confirmation portal **until July 22, 2026**.
3. If you need to withdraw after the deadline of July 22, 2026, you are requested to provide a written statement reflecting the reasons for this decision to uegweek.abstract@abstractserver.com. Please note that UEG cannot guarantee any changes to its printed materials after the deadline.

Publication and copyrights:

1. Accepted clinical cases will be published on the congress platform and the UEG website. UEG requires an exclusive licence to publish the accepted case, which you need to grant on behalf of all authors of the case as part of your submission of a case for UEG Week.
2. Please refer to the [Terms & Conditions](#) for information about UEG's Disclosure Policy (point 8), License to UEG for Publication of Abstracts (point 9) and Permission for Publication (point 10).

Further Information

If you have any additional questions or need further information concerning abstract submission, please contact:

UEG Week 2026 Abstract Management

E-Mail: uegweek.abstract@abstractserver.com

Office Opening Hours:

Monday to Friday 09:00 – 17:00 CET